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mercial deer producers could benefit from
a vaccine that prevents PrPCWD infection.
A previous vaccine study involving prion
peptide sequences identified two conjugate sequences, peptides 4 and 6, that
induced a delay in clinical disease onset
and prolonged survivorship in mice challenged with Rocky Mountain Laboratory
mouse-adapted scrapie (Pilon et al., 2007).
Here we describe a study in which mule
deer were vaccinated with the cervid
forms of peptides 4 and 6 and challenged
via exposure to a PrPCWD-contaminated
environment. We assessed the combined
vaccines’ ability to prevent PrPCWD infection in this species.
Peptide 4 (168-VDQYNNQNTFVHDC-182) and peptide 6 (145- NDYEDRYYRENMYRYPNQ-164) were prepared as described by Pilon et al. (2007)
with the exception of increased scale of
conjugation and supplier of peptide (Midwest Bio-tech, Inc., Fishers, Indiana,
USA). Peptides 4 and 6 were 85.7%
identical (100% similar) and 94.7% identical (100% similar) to peptides 4 and 6
respectively in the mouse study. Peptide 6
was synthesized with a C-terminal linker
containing a glycine and cysteine for
sulfhydryl-mediated conjugation to blue
carrier protein (BCP; Biosonda, Santiago,
Chile). Peptide 4 was conjugated using the
cysteine amino acid at the carboxyl
terminus of the peptide. Both peptides
were .90% pure. Next, 22 mmol of each
peptide was conjugated separately to BCP

ABSTRACT:
Chronic wasting disease (CWD)
adversely affects both wild and captive cervid
populations. A vaccine to prevent CWD
would be a highly desirable tool to aid in
disease management. To this end, we tested
in mule deer a combination of CWD vaccines
consisting of cervid prion peptide sequences
168-VDQYNNQNTFVHDC-182 and 145NDYEDRYYRENMYRYPNQ-164 that had
previously been shown to delay onset of
clinical disease and increase survival in a
mouse-adapted scrapie model. Thirteen captive mule deer (Odocoileus hemionus) were
divided into vaccine (n57) and control groups
(n56), and given prime and boost vaccinations intramuscularly 5 wk apart. Eight weeks
postprime (3 wk postboost), all animals were
challenged via natural exposure to an environment contaminated with infective CWD
prions. Deer were monitored intermittently
for prion infection by rectal and tonsil
biopsies beginning 275 days postchallenge.
All vaccinates responded to both peptide
conjugates present in the combination vaccine
as measured by enzyme-linked immunosorbent assay. However, all deer eventually
became infected regardless of vaccine status.
Key words: Cervid, chronic wasting disease, mule deer, prion, vaccine.

Chronic wasting disease (CWD), caused
by infectious cervid prion (PrP CWD ),
affects several North American species,
including mule deer (Odocoileus hemionus; Williams and Young, 1980). In
western North America, the expansion of
CWD coincided with population declines
of up to 50% in some areas (Miller et al.,
2008b). The captive deer industry also has
been significantly impacted (Spraker et al.,
2009). Both wildlife managers and com694
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using the linker reagent sulfosuccinimidyl
4-(N-maleimidomethyl) cyclohexane-1carboxylate (Sulfo-SMCC, Pierce, Rockford, Illinois, USA). Peptide conjugates
were dialyzed into 2 L phosphate-buffered
saline (PBS) overnight using 10K molecular weight cutoff dialysis membranes.
Protein concentration was determined by
bicinchoninic acid assay and formulated
into an oil-in-water emulsion with mollusk
stabilizing buffer (MSB) (30 mM phosphate; 400 mM NaCl; 41 mM sucrose;
pH57.4) and an adjuvant (AdjuvacTM;
Miller et al., 2000). The final peptide
conjugate concentration was 1 mg/mL.
In November 2005, thirteen 6-monthold mule deer were acquired from a
CWD-free research herd at Washington
State University, Pullman, Washington,
USA. Animals were transported to the
United States Department of Agriculture
(USDA) Animal and Plant Health Inspection Service (APHIS)/Animal Population
Health Institute, Wildlife Research Facility, Colorado State University, Fort Collins, Colorado, USA.
In January, 2007 seven deer were vaccinated in each hip with 3 mL (1 mg/mL) of
each vaccine for a total of 6 mg via
intramuscular (IM) injection. A booster
was administered 5 wk postprime as described above. Six control deer were injected as described above using MSB. Three
weeks postbooster animals were transferred
to the Colorado Division of Parks and
Wildlife (CDPW), Foothills Wildlife Research Facility, Fort Collins, Colorado, for
natural challenge. Deer were placed in a
0.04-ha paddock that was contaminated with
PrPCWD from previous CWD studies conducted on the premises (Miller et al., 2012).
The study protocol was approved by the
USDA APHIS National Wildlife Research
Center and the CDPW institutional animal
care and use committees (IACUC).
Prior to vaccination, EDTA whole blood
was collected for genetic testing as described by Spraker et al. (2002). Serum
was collected for analysis by enzymelinked immunosorbent assay (ELISA)
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before prime and booster, and at 3, 7, 9,
15, and 21 mo postchallenge. For the
ELISAs, peptides were conjugated to
maleic anhydride plates (Thermo Scientific, Rockford, Illinois, USA) following manufacturer’s instructions at 12.5 mg/mL.
Plates were blocked with SeaBlock (1:10)
(Pierce). Serum was diluted in PBS and
incubated 2 hr at 37 C covered with
parafilm. Plates were washed twice with
200 ml PBS containing 0.05% v/v tween-20,
and incubated at 37 C for 1 hr with 200 mL
1:500 goat-antideer IgG horseradish peroxidase–conjugated antibody (Kirkegaard
and Perry Laboratories, Gaithersberg,
Maryland, USA) diluted 1:2000 in PBS.
Fifty microliters 3,39,5,59-tetramethylbenzidine (Pierce) was added to wells, incubated at 37 C for 5 min, and quenched with
13 mL of 2M H2SO4. Plates were read at
450 mm (Opsys plate reader, Dynex
Technologies, Chantilly, Virginia, USA).
Prior to prime vaccination, rectal biopsies were collected to determine CWD
status (Wolfe et al., 2007); all animals were
CWD free. At 9, 15, and 21 mo postchallenge, rectal and tonsillar biopsies
(Wolfe et al., 2002) were collected under
sedation using ketamine hydrochloride
(KetasetH, Fort Dodge Animal Health,
Fort Dodge, Iowa, USA; 7 mg/kg IM) and
xylazine hydrochloride (AnaSedH, Lloyd,
Inc., Shenandoah, Iowa, USA; 0.7 mg/kg
IM). Lymphoid tissues were collected
from alternating tonsils and rectal lymphoid tissue collected from a new location
each time. Tissues were fixed in 10%
buffered formalin and prepared for histologic examination and immunohistochemistry as described by Spraker et al. (2006,
2009). Positive animals were defined as
having positively staining follicles in rectal
or tonsil tissue.
As animals became CWD positive on
biopsy, they were anesthetized with tiletamine hydrochloride/zolazepam (TelazolH,
Fort Dodge Animal Health; 3–5 mg/kg IM)
and xylazine hydrochloride (2.5 to 3.3
mg/kg IM) and euthanized with pentobarbital solution (90–150 mg/kg intravenously
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TABLE 1. Results of vaccine efficacy trial for chronic wasting disease in mule deer (Odocoileus hemionus) in
Colorado, USA, 2007. Number of biopsy-positive mule deer over total sampled per group, their identification
numbers, and the cumulative proportion infected at each time point after exposure to a PrPCWDcontaminated pen.
Vaccinates
Time
postexposure (mos )

No. positive/
total sampled

9
15
21

3/7
0/4
4/4

a

ID No.

1NV, 2KY, 27
1BI, 1BR,
1NE, 34

Controls
Proportion
infected

No. positive/
total sampled

ID No.

Proportion
infected

0.43
0.43
1.0

1/6
2/5a
2/2

26
O, H
2BI, 22S

0.17
0.5a
0.83a

One control died 13 months postexposure and was negative at that time.

[IV]) or potassium chloride (400–1000 mEq
IV). As the IACUC-determined study
endpoint was disease status, and for
humane reasons, we did not allow progression to clinical disease once we determined
an animal biopsy positive. Necropsy was
performed and tissues were collected for
histologic examination: parotid, mandibular, retropharyngeal, mesenteric, ileocecocolic, abomasal, ruminal, hepatic, popliteal,
prescapular, and internal iliac lymph nodes;
nictitans; palatine tonsil; laryngeal tonsil;
obex; brain; lung; heart; liver; kidney;
spleen; bone marrow; spinal cord; muscle;
Peyer’s patches; ovary; uterus; and cervix.
Genetic analysis indicated all animals
were wild type (SS) at codon 225.
Genotypic variation at codon 225 may
influence the progression of CWD in mule
deer. Deer expressing polymorphism SF
experience decreased disease progression
as compared to those expressing SS
(Jewell et al., 2005; Fox et al., 2006).
Because the deer were all SS, it is unlikely
that the study outcome was influenced by
genetic variation; however, the contribution of other genes and PrP-flanking
regions to disease susceptibility or resistance is not completely understood and
these cannot be ruled out as factors in the
efficacy of the vaccine. We also do not
know how SF deer might have responded
to this vaccine.
Infection rates and cumulative proportion infected over time were compared
between treatment groups using one-sided

Fisher exact test performed in WinPepi
(Abramson, 2011). Statistical priority was
placed on minimizing chance of type II
error in the face of small sample size.
Therefore, statistical significance was considered at P#0.1. By 21 mo postexposure
12 deer showed evidence of prion infection regardless of vaccine status (Table 1).
One control died 13 mo postexposure and
was negative. All lymphoid tissues and
sections of brain were positive for
PrPCWD. Significant differences in overall
infection rates and cumulative proportion
infected over time were not detected
between treatment groups (one-sided
Fisher exact P$0.32; Table 1).
Vaccinates produced an antibody response to both peptide-conjugate vaccines
5 wk postprime vaccination (Fig. 1). The
vaccine containing peptide 6 appeared to
generate a stronger immune response;
however, the immune response was transient, as an immediate decrease in absorbance was seen 3 mo postchallenge and no
detectable signal observed after approximately 1 yr postboost (data not shown).
No apparent relationship between ELISA
absorbance and CWD detection was
observed, as animals with high and low
ELISA absorbance were CWD positive at
the first and last time points (Table 1;
Fig. 1).
Intramuscular administration of the two
peptide-BCP conjugate vaccines formulated in Adjuvac did not prevent development of lesions associated with CWD in
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FIGURE 1. Humoral immune responses in mule
deer (Odocoileus hemionus), as measured by enzyme-linked immunosorbent assay to intramuscular
vaccination with 3 mg each of cervid prion peptide
sequences 168-VDQYNNQNTFVHDC-182 and
145-NDYEDRYYRENMYRYPNQ-164 conjugated
to blue carrier protein and administered with
Adjuvac. Responses to both peptides were measured
5 weeks postprime vaccination. Seven vaccinates are
represented: Animal identification (ID) 34, 27 1BI,
1NV, 1BR, 2KY, and 1NE. Four control deer are
represented: Animal ID TR, 26, 2BI, and 22S.

mule deer naturally exposed to PrPCWD at
this dosage level. The amount of total
antigen delivered to the deer was approximately 20 times lower relative to the
original mouse study and was chosen
based on our development of this vaccine
system (Miller et al., 1997, 2000, 2008a).
In previous studies, adequate antibody
responses and vaccine effect were produced with lower antigen loads in deer as
compared to rodents. Additionally, there is
concern regarding autoimmune reactions
with high self-antigen loads. At this dosing
level, our vaccine combination may not
have elicited a sufficient antibody response needed to achieve clinical effect.
No clinical signs indicating autoimmune
reaction were observed, suggesting higher
antigen concentrations or increased dosing
may be used without adverse events.
The lack of vaccine protection we
observed may be due to inadequate
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antigen load; however, route of vaccination, species–specific immunologic differences, method of disease challenge, or
combinations thereof cannot be ruled out.
Our findings emphasize the importance of
continuing the search for a vaccine
candidate using the target species model
in a natural challenge environment.
We acknowledge the following individuals for their valuable time and assistance
with this work: Tracy Sirochman, Michael
Sirochman, Karl Held, Mike Lavelle,
Justin Fischer, Seth Nienhauser, Richanne Lomkin, and Tara Rigg, and other
volunteers and seasonal assistants. This
work was supported by the USDA/APHIS
Science Fellow program and the Colorado
Division of Parks and Wildlife.
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